FDA Will Not Be “Health SEC,” Chief Counsel Troy Tells Investors
This article was originally published in The Gray Sheet
Executive Summary
FDA and the Securities & Exchange Commission are making progress on formalizing communications about potentially misleading disclosures to investors, FDA Chief Counsel Dan Troy told attendees of a Schwab Washington Research Group conference May 15
You may also be interested in...
CDRH More Reliant On SEC, FTC For Ad/Promotion Vigilance Under Policy Shift
The Center for Devices & Radiological Health increasingly is looking to other federal agencies to help regulate medical device advertising and promotion as it scales back its own claim enforcement activities
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.